ProstaLund signs distribution agreement for the UK market

14 January 2022 - 15:15

ProstaLund AB has signed an exclusive distribution agreement with the British company iUrology.

In line with the stated strategy, after acquiring a substantial base in its home market, ProstaLund is now starting its internationalization outside the Nordic region with an initial agreement regarding a collaboration with the British company iUrology.

ProstaLund's product CoreFlow® - Soft Stent has been particularly interesting in view of the current pandemic as it can be used both for patients waiting for BPE surgery and in patients with acute urinary retention. In the evaluation and discussions with the English urologists, the entire portfolio has been presented and there is obviously a curiosity also for heat treatment with CoreTherm as well as for the Schelin catheter as a stand-alone product for local anesthesia of the prostate prior to BPH procedures other than CoreTherm.

Shakeel Osman, CEO iUrology, comments: “We have evaluated ProstaLund's products during the fall 2021. The dialogues we have had with urologists in England have been very positive and we see that ProstaLund's portfolio is of interest to the UK market. In the short-term Covid-19 bothers us, but we have high hopes as soon as the restrictions are eased.”

“This agreement is important for the future. It is unlikely that it will have a significant impact to our sales in 2022, but it gives us a good basis for the next few years.", says CEO Johan Wennerholm.

Provided by: MFN
Nasdaq First North GM (Sweden)
Prostalund AB
Prostalund is a medical technology company engaged in development of products and treatments in urology....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More